Prevalence of Serotype 19A *Streptococcus pneumoniae* among Isolates from U.S. Children in 2005-2006 and Activity of Faropenem

Running Title: Serotype 19A *Streptococcus pneumoniae* and faropenem

Ian A. Critchley,¹* Michael R. Jacobs,² Steven D. Brown,³ Maria M. Traczewski,³ Glenn S. Tillotson,⁴ and Nebojsa Janjic¹

Replidyne, Inc., Louisville, Colorado 80027,¹ Department of Pathology, Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, Ohio 44106², Clinical Microbiology Institute, Wilsonville, Oregon 97070³; and Replidyne, Inc., Milford, Connecticut 06460⁴

*Corresponding author:

Mailing address:

Replidyne Inc.

1450 Infinite Drive

Louisville

Colorado 80027

USA

Phone: (303) 996-5531

Fax: (303) 996 5599

E-mail: icritchley@replidyne.com
ABSTRACT

Of 393 isolates of *Streptococcus pneumoniae* from U.S. children in 2005-2006, non-vaccine serotypes accounted for 89.1% of isolates, with serotype 19A the most prevalent, representing 30.5% of all isolates. \( \text{MIC}_{90} \) of faropenem against serotype 19A isolates was 1 µg/ml, compared to \( \geq 8 \) µg/ml against amoxicillin/clavulanate, cefdinir, cefuroxime axetil and azithromycin.
Streptococcus pneumoniae continues to be a leading cause of respiratory tract infections in both children and adults (25). Although antimicrobial agents such as the β-lactams and macrolides have been widely used to manage such infections their success continues to be compromised by increasing resistance, especially among isolates from young children (20). An alternative and attractive solution to the emergence of resistance has been the development and use of pneumococcal conjugate vaccines that would not only prevent a proportion of invasive pneumococcal disease (IPD) but also reduce the carriage of vaccine serotypes including resistant phenotypes (31, 34). The heptavalent pneumococcal conjugate vaccine (PCV7) was approved in the U.S. in 2000 and recommended for use in all children less than 2 years old (1). At that time the serotypes covered by PCV7 (4, 6B, 9V, 14, 18C, 19F and 23F) accounted for more than 80% of isolates causing IPD among U.S. children (2, 6, 18). Widespread use of PCV7 was initially hailed as a success resulting in a major decline in invasive pneumococcal infections, including those caused by resistant strains (4, 19, 32, 34). Unfortunately, there is now increasing concern regarding the development and spread of resistance among serotypes that are not covered by PCV7 (22, 24, 26). In particular, recent attention has focused on the non-vaccine serotype 19A strains of S. pneumoniae because of their resistance to currently approved antibiotics and their association with clinical failures in children with acute otitis media (29).

Faropenem is an oral penem that is being developed for community-acquired respiratory tract infections in adults and children (30). The objective of this study was to assess the serotype distribution and antimicrobial susceptibility of isolates of S. pneumoniae collected from 393 U.S. children in 2005-2006. The activities of faropenem
and other agents against the most prevalent serotypes of *S. pneumoniae*, including 19A, were evaluated.

*S. pneumoniae* isolates were prospectively collected from 104 participating institutions geographically distributed across the United States. The isolates were limited to one per patient and were collected from a variety of specimen sources that were classified as non-invasive (sputum, bronchoalveolar lavage, tracheal aspirate, ear and sinus), invasive (blood) or carriage (nasopharynx). All isolates were shipped to a central laboratory (CMI, Inc., Wilsonville, OR) where each isolate was sub-cultured and re-identified by standard methods. All isolates were tested for their susceptibility to faropenem, amoxicillin-clavulanate, cefdinir, cefuroxime, penicillin, azithromycin, telithromycin, levofloxacin and trimethoprim-sulfamethoxazole (SXT). Antimicrobial susceptibility testing was conducted by determination of MICs by broth microdilution using frozen panels that were prepared at CMI, Inc., in accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines (7). MICs were interpreted according to CLSI recommendations (8), with the exception of faropenem, for which no CLSI breakpoints are available. The breakpoints for penicillin were those described in CLSI document M100 S-17 (8).

All isolates were serotyped at a central laboratory (Case Western Reserve University, Cleveland, OH). Serotyping was conducted by the quellung reaction using type specific antisera (Statens Serum Institute, Copenhagen, Denmark). Serotypes were classified into two groups: PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F and 23F), and non-PCV7 serotypes (all other serotypes). Isolates identified as serotype 6A were recorded as serotype 6A/C as the newly recognized serotype 6C cross-reacts with 6A (27).
Eighty sites collected *S. pneumoniae* isolates from subjects ≤14 years old with a mean number of five isolates per site. Breakdown of isolates by specimen sources was 17.8% (70 isolates) from invasive sources (blood), 63.1% (248 isolates) non-invasive sources including; sputum, broncho-alveolar lavage, tracheal aspirate, ear and sinus, and 18.8% (74 isolates) were carriage isolates (nasopharynx) and 0.3% (1 isolate) was from an unspecified specimen source. The results in Fig. 1 show the predominant serotype distributions for the 393 clinical isolates of *S. pneumoniae* collected in the study. Only 43 isolates (10.9%) were serotypes included in PCV7 (vaccine serotypes). The most prevalent vaccine serotype was 19F accounting for 5.3% of all isolates. In contrast, 89.1% of the isolates were non-PCV7 serotypes. The most prevalent non-PCV7 serotype was 19A accounting for 30.5% (120 isolates) of all isolates.

In total, 70% (84 isolates) of the serotype 19A strains were isolated from children ≤2 years old. The prevalence of serotype 19A strains from children aged 3-5 years and 6-14 years was 22.5% and 7.5% respectively. Analysis of isolate specimen sources showed that 23.3% of the isolates were from invasive sources such as blood, while 60.8% were from non-invasive sources and 15% from carriage sites. The prevalence of serotype 19A strains by U.S. geographic region was as follows: north central (28.2%), north east (32.2%), northwest (21.4%), south central (37.1%), south east (26.5%) and south west (27.6%) (\(P = 0.71\)).

The results in Table 1 show the comparative activities of faropenem and other agents against the most prevalent serotypes (those with ≥10 isolates) of *S. pneumoniae* (19A, 6A/C, 3, 19F, 35B, 23A, 15A, 33 and 22). Among the oral β-lactams, faropenem had the lowest MIC\(_{90}\) against the 120 serotype 19A isolates (1 µg/ml), which was 8-fold
lower than that of amoxicillin-clavulanate (8 µg/mL), with 35% of the isolates resistant to this agent. The MIC\textsubscript{90} s for cefdinir, cefuroxime axetil, azithromycin and SXT against serotype 19A strains were; >8, 16, >16 and >8 µg/mL, respectively, with resistance rates that were >50% for all four agents. All serotype 19A isolates were susceptible to levofloxacin and 99.2% of the isolates were susceptible to telithromycin. The other serotype with reduced susceptibility to many antimicrobial agents was serotype 19F, a PCV7 serotype. Faropenem also had the lowest MIC\textsubscript{90} for oral β-lactams (1 µg/mL) against this serotype, compared to 16 µg/mL for amoxicillin-clavulanate, with 47.6% of the isolates resistant to the latter agent. Cefdinir, cefuroxime axetil, azithromycin and SXT had MIC\textsubscript{90} s of >8, 32, >16 and >8 µg/mL against serotype 19F strains, with resistance rates of 67%, 67%, 71% and 53% respectively. The next serotype to demonstrate reduced susceptibility to commonly used agents was serotype 35B. The MIC\textsubscript{90} s for faropenem and amoxicillin-clavulanate were 0.5 and 2 µg/mL, respectively, and all isolates were susceptible to amoxicillin-clavulanate. Serotype 35B isolates had reduced susceptibility to cefdinir and azithromycin (MIC\textsubscript{90} s of 4 and 16 µg/mL respectively) but were susceptible to SXT (MIC\textsubscript{90}, 1 µg/mL). Strains belonging to serotypes 3, 23A, 15A, 33 and 22 were all susceptible to penicillin and other β-lactams. Serotype 3 and 22 strains were the only serotypes in this group where almost all isolates were susceptible to azithromycin (MIC\textsubscript{90} s of 0.5 and ≤0.12 µg/mL respectively).

Analysis of resistance phenotypes among serotype 19A isolates shows that 76.7% were resistant to one or more antimicrobial agents, with 51.6% resistant to ≥3 classes of agents and 43.3% to 4 agents (penicillin, cefuroxime, azithromycin and SXT).
The 30.5% prevalence of serotype 19A demonstrated in this study is 11.5% higher than the prevalence of this serotype reported in PROTEKT US study conducted in 2004-2005 (14). There is increasing concern regarding the emergence of 19A serotypes because of their virulence and increased resistance to multiple classes of antimicrobial agents (13, 14, 23, 28, 29). Serotype 19A strains identified in one study were resistant to all antibiotics approved by the FDA for use in children with acute otitis media (29).

Furthermore, clinical failures were observed in this study with the use of high dose amoxicillin, amoxicillin/clavulanate and ceftriaxone in treating 4 children with acute otitis media (AOM) (29). An additional five children at the same practice with AOM caused by serotype 19A *S. pneumoniae* were successfully treated with levofloxacin, an agent unlikely to be widely used to treat pediatric infections because of concerns regarding safety and the potential for resistance development. Although serotype 19A and other non-PCV7 serotypes are pervasive among children they are also increasingly prevalent in the adult and elderly populations (15, 24).

Several investigators have compared the antimicrobial susceptibilities of PCV7 and non-PCV7 serotypes; however, there is little information on how many of the common serotypes vary in their susceptibility to antimicrobial agents. In this study we found that serotypes 19F and 19A were the least susceptible to many commonly used antibiotics. Although the serotype 19F and 19A isolates in our study were not characterized molecularly, the majority of the isolates were resistant to azithromycin (52.4 and 73.3% resistant respectively), and may contain both *mef* and *erm* resistance determinants similar to the serotype 19 strains characterized in other studies (13, 33).
As more than 50% of the serotype 19A strains identified in this study were multi-resistant to ≥3 antimicrobial classes, including all currently available oral β-lactams and macrolides, these strains are attracting considerable attention because they now represent the most prevalent serotype among U.S. pediatric isolates. All isolates were susceptible to levofloxacin and telithromycin, agents that are unlikely to be widely used in children because of safety concerns, and telithromycin is not available in pediatric formulation.

Faropenem appears to be a possible option for treating pediatric infections because it has low potential for resistance development (21), provided it achieves adequate in vivo activity against U.S. pediatric isolates such as serotype 19A that are notoriously resistant to other antimicrobial agents (10, 11). Phase 3 studies in adults have shown that faropenem has a good safety profile with a low incidence of diarrhea, nausea, vomiting and no risk of cardiotoxicity or seizures (12, 16). Although the MIC₉₀ for faropenem and serotype 19A strains is 1 µg/mL, faropenem has demonstrated in vivo efficacy against MDR S. pneumoniae strains with MICs as high as 2 µg/mL in a murine neutropenic thigh infection model (9). In vivo pharmacodynamic (PD) studies of faropenem administered as the medoxomil ester have shown that the percent time above MIC (%T>MIC) for free faropenem required for stasis was similar for S. pneumoniae strains over a wide range of MICs with a mean %T>MIC being required for 13.9% (95% CI 6.34; 21.5%) of the dosing interval (9). In another PD study, the %T>MIC for free faropenem was 16.4% for survival in a lethal murine Bacillus anthracis inhalation post exposure prophylaxis model (17).

In Phase III clinical trials the clinical and microbiological success rates for faropenem were 90% (19/21) for non-MDR S. pneumoniae and 80% (16/20) for MDR S.
*pneumoniae*, while MIC\textsubscript{90}s of faropenem against these groups were 0.25 and 2 µg/mL, respectively (35). Bacteriologic outcome data at day 4 to 6 from a dose-ranging study on children with AOM suggest that dosing regimens of ≥15 mg/kg/day in two divided doses will achieve the pharmacokinetic target required to eradicate MDR *S. pneumoniae* (3).

In conclusion, these results highlight the importance of continued surveillance not only to monitor the emergence of resistance phenotypes but also serotypes of *S. pneumoniae*. The non-PCV7 serotypes now account for the majority of serotypes, with multi-resistant serotype 19A being the most prevalent, suggesting that vaccines may only be a partial solution to prevent IPD with MDR strains because of the continuing emergence of new vaccine escape recombinants (5). These data also highlight the need for new and safe agents that can be used in the pediatric setting that can be used with low propensity for resistance development. The investigational agent, faropenem, demonstrated lower MICs than other β-lactams and macrolides against serotype 19A strains. Further studies are warranted to evaluate the efficacy of faropenem against infections caused by resistant pneumococci including the MDR serotype 19A strains.

**REFERENCES**


   Schaffner, C. Lexau, K. Gershman, A. Reingold, M. Farley, L. H. Harrison, J.
   H. Hadler, N. M. Bennett, A. R. Thomas, L. McGee, T. Pilishvili, A. B.
   snapshot of emergent *Streptococcus pneumoniae* serotype 19A in the United States,


   2005. Postvaccine genetic structure of *Streptococcus pneumoniae* serotype 19A

27. Park, I. H., D. G. Pritchard, R. Cartee, A. Brandao, M. C. Brandileone, and M.
   H. Nahm. 2007. Discovery of a new capsular serotype (6C) within serogroup 6 of

28. Pelton, S. I., H. Huot, J. A. Finkelstein, C. J. Bishop, K. K. Hsu, J. Kellenberg,
   S. S. Huang, R. Goldstein, and W. P. Hanage. 2007. Emergence of 19A as
   virulent and multidrug resistant Pneumococcus in Massachusetts following
   universal immunization of infants with pneumococcal conjugate vaccine. Pediatr.


34. **Whitney, C. G., M. M. Farley, J. Hadler, L. H. Harrison, N. M. Bennett, R. Lynfield, A. Reingold, P. R. Cieslak, T. Pilishvili, D. Jackson, R. R. Facklam, J.**

TABLE 1. Antimicrobial susceptibilities of the nine most prevalent serotypes of *S. pneumoniae* collected from U.S. children in 2005-2006. Amoxicillin/clavulanate results expressed as amoxicillin component and SXT results as trimethoprim component.

<table>
<thead>
<tr>
<th>Serotype</th>
<th>No. of isolates</th>
<th>Percent prevalence</th>
<th>Faropenem (\text{MIC}_{90}) (\text{µg/ml})</th>
<th>Amoxicillin/Clavulanate (\text{MIC}_{90}) (\text{µg/ml})</th>
<th>Cefdinir (\text{MIC}_{90}) (\text{µg/ml})</th>
<th>Cefuroxime axetil (\text{MIC}_{90}) (\text{µg/ml})</th>
<th>Penicillin (\text{MIC}_{90}) (\text{µg/ml})</th>
<th>Azithromycin (\text{MIC}_{90}) (\text{µg/ml})</th>
<th>SXT (\text{MIC}_{90}) (\text{µg/ml})</th>
<th>Telithromycin (\text{MIC}_{90}) (\text{µg/ml})</th>
<th>Levofloxacin (\text{MIC}_{90}) (\text{µg/ml})</th>
</tr>
</thead>
<tbody>
<tr>
<td>19A</td>
<td>120</td>
<td>30.5</td>
<td>1</td>
<td>8 (62/3/35)</td>
<td>&gt;8 (46/2/53)</td>
<td>16 (46/2/52)</td>
<td>4 (13/36/50)</td>
<td>&gt;16 (36/0/64)</td>
<td>&gt;8 (22/0/53)</td>
<td>1 (99/1/0)</td>
<td>1 (100/0/0)</td>
</tr>
<tr>
<td>6A/C</td>
<td>39</td>
<td>9.9</td>
<td>0.25</td>
<td>1 (97/0/3)</td>
<td>2 (59/26/15)</td>
<td>4 (64/23/15)</td>
<td>1 (23/69/8)</td>
<td>8 (31/0/69)</td>
<td>8 (51/3/6)</td>
<td>0.25 (100/0/0)</td>
<td>1 (100/0/0)</td>
</tr>
<tr>
<td>3</td>
<td>29</td>
<td>7.4</td>
<td>0.015</td>
<td>≤0.12 (100/0/0)</td>
<td>0.12 (100/0/0)</td>
<td>≤0.5 (100/0/0)</td>
<td>≤0.03 (100/0/0)</td>
<td>0.5 (93/3/4)</td>
<td>0.25 (100/0/0)</td>
<td>≤0.12 (100/0/0)</td>
<td>2 (97/3/0)</td>
</tr>
<tr>
<td>19F</td>
<td>21</td>
<td>5.3</td>
<td>1</td>
<td>16 (47/5/48)</td>
<td>&gt;8 (33/0/67)</td>
<td>32 (33/0/67)</td>
<td>&gt;4 (33/0/67)</td>
<td>&gt;16 (29/0/71)</td>
<td>&gt;8 (33/1/83)</td>
<td>1 (100/0/0)</td>
<td>1 (100/0/0)</td>
</tr>
<tr>
<td>35B</td>
<td>15</td>
<td>3.8</td>
<td>0.5</td>
<td>2 (100/0/0)</td>
<td>4 (0/0/100)</td>
<td>4 (0/0/100)</td>
<td>2 (0/0/100)</td>
<td>16 (73/0/27)</td>
<td>1 (87/4/87)</td>
<td>0.5 (100/0/0)</td>
<td>1 (100/0/0)</td>
</tr>
<tr>
<td>23A</td>
<td>14</td>
<td>3.6</td>
<td>0.06</td>
<td>0.25 (100/0/0)</td>
<td>0.5 (93/7/0)</td>
<td>1 (93/7/0)</td>
<td>0.5 (57/43/0)</td>
<td>&gt;16 (79/21/0)</td>
<td>0.5 (93/2/79)</td>
<td>≤0.12 (100/0/0)</td>
<td>1 (100/0/0)</td>
</tr>
<tr>
<td>15A</td>
<td>14</td>
<td>3.6</td>
<td>0.12</td>
<td>0.25 (100/0/0)</td>
<td>1 (72/21/7)</td>
<td>4 (72/21/7)</td>
<td>0.5 (7/93/0)</td>
<td>&gt;16 (70/2/93)</td>
<td>4 (50/30/14)</td>
<td>≤0.12 (100/0/0)</td>
<td>1 (100/0/0)</td>
</tr>
<tr>
<td>33</td>
<td>12</td>
<td>3.1</td>
<td>0.015</td>
<td>≤0.12 (100/0/0)</td>
<td>0.12 (100/0/0)</td>
<td>≤0.5 (100/0/0)</td>
<td>≤0.03 (92/8/0)</td>
<td>16 (42/58/0)</td>
<td>2 (0/100)</td>
<td>0.25 (100/0/0)</td>
<td>1 (100/0/0)</td>
</tr>
<tr>
<td>22</td>
<td>10</td>
<td>2.5</td>
<td>0.015</td>
<td>≤0.12 (100/0/0)</td>
<td>0.12 (100/0/0)</td>
<td>≤0.5 (100/0/0)</td>
<td>≤0.03 (100/0/0)</td>
<td>≤0.12 (100/0/0)</td>
<td>0.25 (100/0/0)</td>
<td>≤0.12 (100/0/0)</td>
<td>1 (100/0/0)</td>
</tr>
<tr>
<td>All isolates</td>
<td>393</td>
<td>100</td>
<td>1</td>
<td>8 (84/2/14)</td>
<td>&gt;8 (68/4/28)</td>
<td>16 (68/4/28)</td>
<td>4 (49/26/25)</td>
<td>&gt;16 (55/1/44)</td>
<td>8 (56/9/35)</td>
<td>1 (99/1/0)</td>
<td>1 (99.7/0.3/0)</td>
</tr>
</tbody>
</table>

*a*MIC\(_{90}\)s are expressed as micrograms per milliliter

*b*Breakpoints not available for faropenem

*c*Serotype included in PCV7

*d*Susceptible / intermediate / resistant breakpoints (µg/ml)